GGrantIndex
← Leaderboards

Joseph S Tash

University Of Kansas Medical Center

$4,247,537
Attributed
$4,247,537
Total exposure
6
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $3.5M · FY200716
$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16

Funding mix

By agency

NIH$13,905,586 · 7

By mechanism

U54$11,874,600 · 4
U01$1,922,920 · 2
P30$108,066 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Kansas Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Design

Research focus

DesignMale Contraceptive AgentsPharmaceutical PreparationsInhibitor/AntagonistSuccessProteinsOralFertilityContraceptive AgentsSmall MoleculeUnited States National Institutes Of HealthDrug DiscoveryEnvironmentDrug DevelopmentBaseAdverse EffectsSiteNational Institute Of Child Health And Human DevelopmentRattusIn VitroIn VivoHormonalInnovationPharmaceutical Chemistry

Grant awards (26)

Cell-cycle regulatory kinases as targets for male contraceptive drug development$311,334
U01 · FY2016 · HD · contact PI
Cell-cycle regulatory kinases as targets for male contraceptive drug development$306,618
U01 · FY2015 · HD · contact PI
H2-Gamendazole analogues as reversible non-hormonal male contraceptive agents$255,422
U01 · FY2015 · HD · contact PI
H2-Gamendazole analogues as reversible non-hormonal male contraceptive agents$254,636
U01 · FY2014 · HD · contact PI
Cell-cycle regulatory kinases as targets for male contraceptive drug development$235,541
U01 · FY2014 · HD · contact PI
H2-Gamendazole analogues as reversible non-hormonal male contraceptive agents$36,335
U01 · FY2014 · HD · contact PI
H2-Gamendazole analogues as reversible non-hormonal male contraceptive agents$248,611
U01 · FY2013 · HD · contact PI
H2-Gamendazole analogues as reversible non-hormonal male contraceptive agents$274,423
U01 · FY2012 · HD · contact PI
Interdisciplinary Center for Male Contraceptive Research and Drug Development$2,386,376
U54 · FY2011 · HD · contact PI
Novel Male Contraceptive Agents that Target HSP90 and Elongation Factor 1A$401,843
U54 · FY2011 · HD · contact PI
Administrative Core-Interdisciplinary Ctr for Male Contraceptive Res & Drug Dev$187,338
U54 · FY2011 · HD · contact PI
Interdisciplinary Center for Male Contraceptive Research and Drug Development$1,532,087
U54 · FY2010 · HD · contact PI
Interdisciplinary Center for Male Contraceptive Research and Drug Development$1,124,456
U54 · FY2010 · HD · contact PI
Novel Male Contraceptive Agents that Target HSP90 and Elongation Factor 1A$442,757
U54 · FY2010 · HD · contact PI
Administrative Core-Interdisciplinary Ctr for Male Contraceptive Res & Drug Dev$442,757
U54 · FY2010 · HD · contact PI
Interdisciplinary Center for Male Contraceptive Research and Drug Development$1,503,438
U54 · FY2009 · HD · contact PI
Novel Male Contraceptive Agents that Target HSP90 and Elongation Factor 1A$299,633
U54 · FY2009 · HD · contact PI
Interdisciplinary Center for Male Contraceptive Research and Drug Development$136,437
U54 · FY2009 · HD · contact PI
Administrative Core-Interdisciplinary Ctr for Male Contraceptive Res & Drug Dev$108,883
U54 · FY2009 · HD · contact PI
Interdisciplinary Center for Male Contraceptive Research and Drug Development$1,475,254
U54 · FY2008 · HD · contact PI
Novel Male Contraceptive Agents that Target HSP90 and Elongation Factor 1A$248,481
U54 · FY2008 · HD · contact PI
Interdisciplinary Center for Male Contraceptive Research and Drug Development$84,859
U54 · FY2008 · HD · contact PI
Interdisciplinary Center for Male Contraceptive Research and Drug Development$1,500,001
U54 · FY2007 · HD · contact PI
CORE--IMAGE ANALYSIS$0
U54 · FY2002 · HD
CORE--IMAGE ANALYSIS$0
U54 · FY2001 · HD
CORE--IMAGE ANALYSIS AND PHOTOGRAPHY$108,066
P30 · FY2000 · HD